RESTON, Va., July 9, 2007 (PRIME NEWSWIRE) -- TenthGate International, Inc. (www.TenthGate.biz), (Pink Sheets:TGTI), ("TenthGate"), an innovative medical holding company focusing on healthcare related life-changing technologies, was the subject of a feature article in the July 6th print edition of the New Mexico Business Weekly written by Kevin Robinson-Avila. The article includes interviews with TenthGate's Chairman and CEO Tim Novak and Dr. Graham Timmins of the University of New Mexico School of Pharmacy.
http://albuquerque.bizjournals.com/albuquerque/stories/2007/07/09/story1.html?b=1183953600^1486938
Working with innovative technologies developed at the University of New Mexico School of Pharmacy by Dr. Graham Timmins, TenthGate's goal is to discover and understand the causation factors of melanoma skin cancer, using Electron Paramagnetic Resonance (EPR) diagnostics at the melanin free radical level to help guide us to specific prevention strategies. Initial technology benefits will be directed at product retailers and manufacturers who can provide a more exact description of the protective effectiveness of their sunscreens and other cosmetic products, allowing consumers to make better informed decisions on responsible sun exposure protective measures. This field of use will likely create initial expansion of job opportunities in New Mexico. TenthGate has made application and are pending trademark approval for 'MPF' for 'Melanocyte Protective Factor,' which will be used to quantitatively describe this new protective efficacy scale in a standardize fashion.
Description of TenthGate's EPR Technology Applications:
http://www.tenthgate.biz/mDP.html
About TenthGate
TenthGate International, Inc. is focused on the acquisition and development of life changing, health related technologies. The range of acquired technologies includes biotech/life sciences, diagnostic and unique medical devices. The Company has acquired several intellectual properties and licenses to date, two of which have obtained FDA approval. The company has obtained exclusive license for an emerging melanoma diagnostic and prevention technology utilizing Electron Paramagnetic Resonance (EPR) technology. TenthGate has identified several additional technologies for acquisition.
The TenthGate International, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3179
About Dr. Graham Timmins
http://hsc.unm.edu/pharmacy/faculty/Graham_Timmins.shtml
Safe Harbor Disclaimer
Except for the historical information contained herein, the matters discussed in this press release may include forward-looking statements or information. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of TenthGate International, Inc., and its affiliates, set forth herein and those preceded by or that include the words "believes," "expects," "given," "targets," "intends," "anticipates," "plans," "projects," "forecasts" or similar expressions, are forward-looking statements. Although the Company's management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties which could cause the Company's future results to differ materially from those anticipated. The Company assumes no obligation to update any of the information contained or referenced in this press release.